TY - JOUR T1 - Gas-fragmentation study of the novel synthetic zwitterionic drug 3-methyl-9-(2-oxa-2lambda5-2H-1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro[5,5]undecane chloride (SLXM-2) by electrospray ionization tandem mass spectrometry. AU - Wang,Siting, AU - Song,Yan, AU - Wang,Jiao, AU - Ling,Xiaomei, AU - Ge,Zemei, AU - Li,Runtao, AU - Cui,Jingrong, PY - 2010/3/20/entrez PY - 2010/3/20/pubmed PY - 2010/6/23/medline SP - 1181 EP - 4 JF - Rapid communications in mass spectrometry : RCM JO - Rapid Commun Mass Spectrom VL - 24 IS - 8 N2 - The zwitterionic drug 3-methyl-9-(2-oxa-2lambda5-2H-1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro[5,5]undecane chloride (SLXM-2) is a novel synthetic compound which has shown anticancer activity and low toxicity in vivo. In this study, the various gas-phase fragmentation routes were analyzed by electrospray ionization mass spectrometry (positive ion mode) in conjunction with tandem mass spectrometry (ESI-MS(n)) for the first time. In ESI-MS the fragment ion at m/z 289 (base peak) was formed by loss of the chlorine anion from the zwitterionic precursor SLXM-2. The fragment ion at m/z 232 was formed from the ion at m/z 289 by loss of 1-methylaziridine. The detailed gas-phase collision-induced dissociation (CID) fragmentation mechanisms obtained from the various precursor ions extracted from the zwitterionic SLXM-2 drug was obtained by tandem mass spectrometry analyses. SN - 1097-0231 UR - https://www.unboundmedicine.com/medline/citation/20301099/Gas_fragmentation_study_of_the_novel_synthetic_zwitterionic_drug_3_methyl_9__2_oxa_2lambda5_2H_132_oxazaphosphorine_2_cyclohexyl__369_triazaspiro[55]undecane_chloride__SLXM_2__by_electrospray_ionization_tandem_mass_spectrometry_ L2 - https://doi.org/10.1002/rcm.4501 DB - PRIME DP - Unbound Medicine ER -